There are about 11304 clinical studies being (or have been) conducted in Denmark. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
The purpose of the study is to investigate pain, anxiety and depression in patients with panic anxiety disorders without pain or depression without pain compared with healthy volunteers
To evaluate the autonomic cardiac function in patients with complex regional pain syndrome
The debilitating effects of immobilisation on muscle strength and size in young individuals are well documented. Moreover, sarcopenia has long been recognized as a major cause of muscle strength loss in old age, however, changes in muscle mass and architecture with immobilisation in the elderly has not previously been investigated. This is contrasted by the fact that the elderly population more often undergoes periods of immobilization and disuse not only due to joint pain but also due to a higher degree of co morbidity and hospitalisation.The purpose of the present study was to compare the effect of a 2 week period of unilateral immobilisation on the physiological muscle cross sectional area, maximal isometric muscle strength, specific force, muscle fascicle length and muscle fibre pennation angle in young and old healthy men.
During the last decades there has been an increase in the relative proportion and life expectancy of elderly people in the industrialised countries. Consequently the amount of elderly with diseases and disabilities related to aging has increased. It therefore appears paramount to gain a better understanding of how disuse and immobilisation affects neuromuscular properties in the elderly, as well as to identify training regimes that ensures an effective rehabilitation.The population of interest in the present study was elderly individuals with long term hip-osteoarthritis undergoing a hip-replacement operation. The study was divided in two parts, a cross-sectional study and an intervention study. The cross-sectional study investigated muscle size, maximal muscle strength, specific force, neural drive and explosive muscle force characteristics in elderly individuals who were affected by unilateral prolonged disuse due to hip-osteoarthritis. The data clearly indicated that the side with hip-osteoarthritis was affected by a marked decrease in muscle mass, maximal muscle strength, neural drive and explosive muscle force characteristics compared to the unaffected side. The intervention study investigated if elderly patients that undergo hip-replacement surgery could benefit from additional training in the early postoperative phase. The data clearly demonstrated that resistance training was an effective and safe way to increase muscle mass, maximal muscle strength, neuromuscular activity, functional performance and decrease the hospitalisation period compared to regimes of conventional rehabilitation regimen or electrical muscle stimulation. Additionally the intervention study demonstrated that resistance training effectively induced marked increases in explosive muscle force characteristics in elderly subjects compared to rehabilitation regimes using electrical muscle stimulation or conventional rehabilitation. Furthermore, the gains in maximal muscle strength and explosive muscle force characteristics were accompanied by significant increases in EMG amplitudes. Furthermore, the demonstration that explosive muscle force capacity of the neuromuscular system remains trainable in elderly recovering from prolonged limb disuse and major surgery may have important implications for future rehabilitation programs, especially when considering the importance of rapid muscle force capacity on postural balance, maximal walking speed and other tasks of daily life actions.
The primary objectives of this trial are (a) to demonstrate that the fixed-dose combination T40/A5 or the fixed-dose combination T80/A5 is superior in reducing blood pressure at eight weeks compared with A5 (b) to demonstrate that the fixed-dose combination T40/A5 or the fixed-dose combination T80/A5 is not inferior in reducing blood pressure at eight weeks compared with A10 and (c) to demonstrate that the incidence of oedema on the fixed-dose combination T40/A5 pooled with the fixed-dose combination T80/A5 is superior (less oedema) to A10 in patients who fail to respond adequately to six weeks treatment with A5.
The aim of this study is to demonstrate that clazosentan, administered as a continuous intravenous infusion at 5 mg/h until Day 14 post aneurysmal subarachnoid hemorrhage (aSAH), reduces the incidence of cerebral vasospasm -related morbidity and all-cause mortality within 6 weeks post-aSAH treated by surgical clipping. The primary endpoint of the study is the occurrence of cerebral vasospasm-related morbidity, and mortality of all-causes within 6 weeks post-aSAH, defined by at least one of the following: 1. Death (all causes). 2. New cerebral infarct(s) due to cerebral vasospasm as either the primary or relevant contributing cause, or not adjudicated to be entirely due to causes other than vasospasm. 3. Delayed ischemic neurological deficit (DIND) due to cerebral vasospasm as either the primary or relevant contributing cause, or not adjudicated to be entirely due to causes other than vasospasm. 4. Neurological signs or symptoms (depending on state of consciousness), in the presence of confirmed cerebral vasospasm on angiography (DSA or CTA), leading to the administration of a valid rescue therapy. An independent Critical Events Committee (CEC) will adjudicate whether or not patients meet the primary endpoint and its individual morbidity components.
The purpose of this study is to determine the effect of AZD0530 on subjects with breast cancer or prostate cancer with metastatic bone disease in comparison to zoledronic acid.
This 2 arm study will evaluate the efficacy, safety, and pharmacokinetics of Tarceva, compared with placebo, following platinum-based chemotherapy in patients with advanced, recurrent, or metastatic NSCLC who have not had disease progression or unacceptable toxicity during chemotherapy. Following 4 cycles of platinum-based chemotherapy, eligible patients will be randomized to receive either Tarceva 150mg po daily, or placebo daily. The anticipated time on study treatment is until disease progression; the target sample size is 500+ individuals.
This 2 arm study will evaluate the efficacy, safety, and pharmacokinetics of Tarceva and that of standard of care chemotherapy in patients with advanced, recurrent, or metastatic NSCLC experiencing disease progression after failure of platinum-based chemotherapy.Eligible patients will be randomized to receive either Tarceva 150mg po daily, or comparator (either Alimta 500mg/m2 every 3 weeks, or Taxotere 75mg/m2 every 3 weeks). The anticipated time on study treatment is until disease progression ,and the target sample size is 500+ individuals.
Investigation of how the patients experience whole body MRA. After the WB-MRA the patients will fill in a questionnaire, that contains questions about the WB-MRA procedure and how the patient felt during the examination. We expect that the patients will report a high degree of satisfaction with the WB-MRA procedure, with little discomfort.